MCNS
MCID: LPD004
MIFTS: 44

Lipoid Nephrosis (MCNS)

Categories: Blood diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Lipoid Nephrosis

MalaCards integrated aliases for Lipoid Nephrosis:

Name: Lipoid Nephrosis 12 15 17 70
Minimal Change Glomerulonephritis 12 6
Minimal Change Disease 12 20
Nephrotic Syndrome with Lesion of Minimal Change Glomerulonephritis 12
Nephrotic Syndrome with Lesion of Minimal Change Nephrotic Syndrome 12
Idiopathic Minimal Change Nephrotic Syndrome 20
Glomerulonephritis, Minimal Change 70
Nephrotic Syndrome, Minimal Change 70
Minimal Change Nephrotic Syndrome 20
Nephrotic Syndrome Minimal Change 54
Minimal Change Glomerulopathy 20
Nephrosis, Lipoid 44
Mcns 20

Classifications:



External Ids:

Disease Ontology 12 DOID:10966
MeSH 44 D009402
NCIt 50 C34844
SNOMED-CT 67 197592009
ICD10 32 N04
UMLS 70 C0027721 C1704320 C1704321

Summaries for Lipoid Nephrosis

GARD : 20 Minimal change disease is a kidney disease in which there is damage to the filtering units of the kidney (glomeruli). It is the most common cause of nephrotic syndrome in children. Nephrotic syndrome is comprised of a group of symptoms including protein in the urine ( proteinuria ), low protein levels in the blood, high cholesterol and triglycerides, an increased risk for blood clots, and swelling. Other features of this disease include weight gain and a foamy appearance of the urine. The cause of minimal change disease is unknown, but it may occur following an allergic reaction or infection. Treatment may involve the use of steroids.

MalaCards based summary : Lipoid Nephrosis, also known as minimal change glomerulonephritis, is related to glomerulonephritis and acute kidney tubular necrosis. An important gene associated with Lipoid Nephrosis is LMX1B (LIM Homeobox Transcription Factor 1 Beta), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Interleukin-10 signaling. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and monocytes, and related phenotype is renal/urinary system.

Wikipedia : 73 Minimal change disease (also known as MCD, minimal change glomerulopathy, and nil disease, among others)... more...

Related Diseases for Lipoid Nephrosis

Diseases related to Lipoid Nephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 glomerulonephritis 31.1 NPHS2 NPHS1 CD79A CCL2 ALB
2 acute kidney tubular necrosis 31.0 NAGLU CCL2 ALB
3 membranoproliferative glomerulonephritis 30.9 NPHS1 CD79A ALB
4 chronic graft versus host disease 30.7 IL10 CD79A
5 tetanus 30.7 IL13 IL10 CD79A ALB
6 pulmonary tuberculosis 30.6 IL10 CCL2 ALB
7 dermatitis, atopic 30.6 SERPINA3 IL4R IL13 IL10 CCL2
8 microvascular complications of diabetes 3 30.5 SERPINB7 NPHS1 NAGLU ALB
9 end stage renal disease 30.5 NPHS2 NPHS1 IL10 CD2AP CCL2 ALB
10 bacterial meningitis 30.5 IL10 CCL2 ALB
11 hypoparathyroidism, sensorineural deafness, and renal disease 30.4 NPHS2 NPHS1 ACTN4
12 nephrotic syndrome, type 2 30.4 NPHS2 NPHS1 CD2AP ACTN4
13 nephrotic syndrome, type 10 30.4 PODXL NPHS2 NPHS1
14 hyper ige syndrome 30.4 IL4R IL13 IL10
15 peritonitis 30.4 IL10 CCL2 ALB
16 nephrosclerosis 30.4 SYNPO NPHS2 NPHS1 CCL2
17 food allergy 30.4 IL4R IL13 IL10 ALB
18 otitis media 30.3 IL10 CD79A ALB
19 ige responsiveness, atopic 30.3 IL4R IL13 IL10
20 nephrotic syndrome, type 1 30.3 NPHS2 NPHS1 CD2AP ACTN4
21 crohn's disease 30.3 IL13 IL10 CCL2 ALB
22 behcet syndrome 30.3 IL13 IL10 CCL2 ALB
23 goodpasture syndrome 30.2 PLA2R1 NPHS1 ALB
24 syphilis 30.2 SERPINA3 CD79A ALB
25 arteriolosclerosis 30.2 SERPINA3 CD79A ALB
26 rapidly progressive glomerulonephritis 30.2 PLA2R1 NPHS1 ALB
27 lipid storage disease 30.1 SERPINA3 CCL2 ALB
28 acute cystitis 30.1 SERPINA3 IL10 CCL2 ALB
29 focal segmental glomerulosclerosis 30.1 SYNPO PODXL NPHS2 NPHS1 LMX1B ITGB1
30 iga glomerulonephritis 30.1 SERPINB7 NPHS2 NPHS1 NAGLU CD79A CD2AP
31 membranous nephropathy 30.0 PODXL PLA2R1 NPHS2 NPHS1 CD79A CD2AP
32 respiratory failure 30.0 SERPINA3 IL13 IL10 CCL2 ALB
33 proteinuria, chronic benign 29.9 SYNPO SERPINB7 NPHS2 NPHS1 NAGLU CD79A
34 glomerular disease 29.9 NAGLU CD79A CD2AP ALB ACTN4
35 nephrotic syndrome 29.9 SYNPO PODXL NPHS2 NPHS1 NAGLU LMX1B
36 skin disease 29.9 SERPINA3 ITGB1 IL13 IL10 CD79A ALB
37 immune deficiency disease 29.9 SERPINA3 IL13 IL10 CD79A CCL2
38 hydronephrosis 29.8 NAGLU CCL2 ALB
39 chronic kidney disease 29.6 SERPINB7 SERPINA3 NPHS2 NPHS1 IL10 CCL2
40 alport syndrome 29.6 SYNPO NPHS2 NPHS1 LMX1B CD2AP ALB
41 familial nephrotic syndrome 29.5 SYNPO PODXL NPHS2 NPHS1 LMX1B CD2AP
42 wilms tumor 1 29.3 SYNPO SERPINA3 PODXL NPHS2 NPHS1 CD2AP
43 systemic lupus erythematosus 29.3 MIR200C IL13 IL10 CD79A CCL2 ALB
44 kidney disease 29.2 SERPINB7 SERPINA3 NPHS2 NPHS1 NAGLU LMX1B
45 c1q nephropathy 11.1
46 focal segmental glomerulosclerosis 10 11.1
47 nephrotic syndrome, type 23 11.1
48 chromium allergic contact dermatitis 10.4 IL13 IL10
49 ceftriaxone allergy 10.4 IL13 IL10
50 cefaclor allergy 10.4 IL13 ALB

Graphical network of the top 20 diseases related to Lipoid Nephrosis:



Diseases related to Lipoid Nephrosis

Symptoms & Phenotypes for Lipoid Nephrosis

MGI Mouse Phenotypes related to Lipoid Nephrosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.32 ACTN4 ALB CD2AP CD79A ITGB1 LMX1B

Drugs & Therapeutics for Lipoid Nephrosis

Drugs for Lipoid Nephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Immunologic Factors Phase 4
13 Vaccines Phase 4
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
15 Cyclosporins Phase 4
16 Calcineurin Inhibitors Phase 4
17 Adrenocorticotropic Hormone Phase 4
18 Melanocyte-Stimulating Hormones Phase 4
19 beta-Endorphin Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antitubercular Agents Phase 4
23 Hormones Phase 4
24 Hormone Antagonists Phase 4
25 glucocorticoids Phase 4
26 Antineoplastic Agents, Hormonal Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Methylprednisolone Acetate Phase 4
29 Hydroxycholecalciferols Phase 4
30 Nutrients Phase 4
31 Trace Elements Phase 4
32 Micronutrients Phase 4
33 Vitamins Phase 4
34 Calciferol Phase 4
35
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
36
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
37
rituximab Approved Phase 3 174722-31-7 10201696
38
Maleic acid Experimental Phase 3 110-16-7 444266
39 Psychotropic Drugs Phase 2, Phase 3
40 Anticonvulsants Phase 2, Phase 3
41 Neurotransmitter Agents Phase 2, Phase 3
42 Histamine Antagonists Phase 3
43 Alkylating Agents Phase 3
44 Antibodies Phase 3
45 Immunoglobulins Phase 3
46 Antineoplastic Agents, Immunological Phase 3
47 Antirheumatic Agents Phase 3
48
Abatacept Approved Phase 2 332348-12-6 10237
49
Zinc oxide Approved Phase 2 1314-13-2
50
Zinc Approved, Investigational Phase 2 7440-66-6 32051

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome Unknown status NCT02649413 Phase 4 Prednisone
2 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
3 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
4 Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
5 Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome Completed NCT01185197 Phase 4 Myfortic plus low-dose steroid;Prednisolone
6 Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease Completed NCT00982072 Phase 4 tacrolimus;prednisolone
7 Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
8 Department of Cardiology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting NCT04519112 Phase 4
9 A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome Unknown status NCT02896270 Phase 2, Phase 3 Valproic Acid
10 A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
11 A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
12 A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study) Completed NCT00981838 Phase 3 Rituximab
13 Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
14 Cyclophosphamide Versus Mycophenolate Mofetil for Children With Steroid-dependent Idiopathic Nephrotic Syndrome : a Multicenter Randomized Controlled Trial Completed NCT01092962 Phase 3 Cyclophosphamide;Mycophenolate mofetil
15 Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome Completed NCT04494438 Phase 3 Rituximab
16 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone Recruiting NCT03298698 Phase 3 Rituximab;Prednisone
17 A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) Completed NCT02592798 Phase 2 Abatacept
18 A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia Completed NCT00509093 Phase 2 imatinib mesylate
19 An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma Completed NCT02730819 Phase 2 Illuminate Cream
20 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Recruiting NCT03970577 Phase 2 Rituximab;Prednisone
21 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Recruiting NCT04387448 Phase 2 GFB-887;Placebo
22 Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Recruiting NCT04009668 Phase 2 adalimumab
23 The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients Recruiting NCT04370288 Phase 1 MCN (Methylene blue, vitamin C, N-acetyl cysteine)
24 A Study on the Diagnosis of Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and Gastroesophageal Reflux Disease Using Linked Color Imaging Unknown status NCT03068572
25 Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease Completed NCT04369183
26 The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy Completed NCT01451710 Prednisone or Prednisolone
27 Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome Completed NCT00577525
28 The Musculocutaneous Nerve (Mcn) in a High Resolution MRI Completed NCT02305875
29 Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome Completed NCT01609426
30 Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics Completed NCT02869893 Secretin
31 INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics) Recruiting NCT01605266
32 Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network Recruiting NCT01209000
33 The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) Recruiting NCT03949972
34 The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project Recruiting NCT03786263
35 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
36 Effect of Daily Transcutaneous Auricular Vagus Nerve (taVNS) Stimulation on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome Recruiting NCT04169776
37 A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood. Recruiting NCT04207580
38 Molecular and Genetic Analysis of Inherited Kidney Dysfunction Active, not recruiting NCT02194582
39 Nephrotic Syndrome Study Network (NEPTUNE) Match Study Enrolling by invitation NCT04571658
40 A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) Suspended NCT04235621

Search NIH Clinical Center for Lipoid Nephrosis

Cochrane evidence based reviews: nephrosis, lipoid

Genetic Tests for Lipoid Nephrosis

Anatomical Context for Lipoid Nephrosis

MalaCards organs/tissues related to Lipoid Nephrosis:

40
Kidney, Myeloid, Monocytes, Thyroid, Bone, Cortex, Endothelial

Publications for Lipoid Nephrosis

Articles related to Lipoid Nephrosis:

(show top 50) (show all 687)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. 54 61
18985619 2009
3
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 54 61
19562271 2009
4
Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. 54 61
9346389 1997
5
Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. 54 61
8247178 1993
6
Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis. 61
31473631 2019
7
[Minimal change disease and focal segmental glomerulosclerosis]. 61
30887070 2019
8
Diagnosis and management of nephrotic syndrome. 61
29020719 2017
9
50 Years Ago in The Journal of Pediatrics: Effect of Cyclophosphamide on Lipoid Nephrosis in the Human and on Aminonucleoside Nephrosis in the Rat. 61
27017462 2016
10
The Treatment of IgA Nephropathy. 61
27536661 2015
11
[Minimal-change glomerulonephritis in chronic lymphocytic leukemia: A clinical case]. 61
26978424 2015
12
Role of Angptl4 in vascular permeability and inflammation. 61
24173241 2014
13
Patterns of childhood nephrotic syndrome in Aljouf region, Saudi Arabia. 61
24029283 2013
14
Interstitial nephritis with moderate-to-heavy proteinuria: an unusual combination. 61
22382248 2012
15
[Hodgkin's disease revealed by a nephrotic syndrome: a case report with literature review]. 61
22123569 2011
16
Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. 61
20886250 2011
17
[Clinical-pathological characteristics of IgM nephropathy in 34 children]. 61
20497638 2010
18
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. 61
19343274 2010
19
Nephrotic syndrome and Guillan-Barré Syndrome: a rare association in child. 61
20061709 2010
20
Genetic effect of the NPHS2 gene variants on proteinuria in minimal change disease and immunoglobulin A nephropathy. 54
20025681 2009
21
Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. 61
19520469 2009
22
[A case of sternoclavicular joint tuberculosis with renal failure due to rifampicin]. 61
19764465 2009
23
Historical development of the renal histopathology services in Malaysia. 54
19694308 2009
24
Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. 61
18927121 2009
25
Mesangioproliferative glomerulonephritis: an important glomerulonephritis in nephrotic syndrome of young adult. 61
18723953 2008
26
[Choroidal effusion after uncomplicated cataract surgery]. 61
18516782 2008
27
Endothelial microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy. 61
18799061 2008
28
[Nephrotic syndrome: don't forget to search for hypothyroidism]. 61
18191306 2008
29
Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. 54
18032547 2008
30
[Graves disease, hypothyroidism, and minimal-change glomerulonephritis]. 61
18454723 2008
31
Quiz page. Minimal change glomerulonephritis associated with secondary syphilis. 61
17687805 2007
32
[Nephrotic syndrome associated with minimal-change glomerulonephritis and chronic lymphocytic leukaemia]. 61
18336109 2007
33
Expression profile of nephrin, podocin, and CD2AP in Chinese children with MCNS and IgA nephropathy. 54
16941146 2006
34
Role of podocyte slit diaphragm as a filtration barrier. 54
16889564 2006
35
Idiopathic reversible renal failure in a young woman with minimal change glomerulonephritis. 61
16903627 2006
36
Minimal change glomerulonephritis in chronic lymphocytic leukemia: pathophysiological and therapeutic aspects. 61
16601371 2006
37
Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. 54
16759810 2006
38
Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome. 54
16739878 2006
39
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 54
16285662 2005
40
Nephrotic syndrome preceding Hodgkin's lymphoma by 13 months. 61
16175948 2005
41
Thin basement membrane nephropathy associated with other glomerular diseases. 61
15880329 2005
42
Nephrotic syndrome after stem cell transplantation. 61
15659148 2005
43
No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. 61
15730048 2005
44
Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome. 54
15687724 2005
45
[History of nephrotic syndrome]. 61
15500117 2004
46
Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). 54
15086927 2004
47
Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. 61
14758527 2004
48
[Pathogenesis of immune glomerulonephritis]. 54
15008213 2003
49
[Lipoid nephrosis in childhood]. 61
15008217 2003
50
[Histological classification of chronic glomerular diseases]. 61
15008214 2003

Variations for Lipoid Nephrosis

ClinVar genetic disease variations for Lipoid Nephrosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LMX1B NM_001174147.2(LMX1B):c.737G>C (p.Arg246Pro) SNV Likely pathogenic 812901 rs1191455921 GRCh37: 9:129455598-129455598
GRCh38: 9:126693319-126693319

Expression for Lipoid Nephrosis

Search GEO for disease gene expression data for Lipoid Nephrosis.

Pathways for Lipoid Nephrosis

GO Terms for Lipoid Nephrosis

Cellular components related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 SERPINA3 PODXL NPHS2 NPHS1 NAGLU ITGB1
2 membrane raft GO:0045121 9.62 PODXL NPHS2 ITGB1 CD79A
3 extracellular space GO:0005615 9.61 SERPINB7 SERPINA3 PODXL IL4R IL13 IL10
4 ruffle GO:0001726 9.54 PODXL ITGB1 CD2AP
5 platelet alpha granule lumen GO:0031093 9.43 SERPINA3 ALB ACTN4
6 slit diaphragm GO:0036057 8.8 PODXL NPHS2 NPHS1

Biological processes related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.55 ITGB1 IL4R IL13 IL10 CCL2
2 B cell differentiation GO:0030183 9.54 ITGB1 IL10 CD79A
3 positive regulation of signaling receptor activity GO:2000273 9.4 ITGB1 IL10
4 glomerular visceral epithelial cell development GO:0072015 9.32 PODXL NPHS1
5 positive regulation of mast cell degranulation GO:0043306 9.26 IL4R IL13
6 positive regulation of macrophage activation GO:0043032 9.13 IL4R IL13 IL10
7 positive regulation of immunoglobulin production GO:0002639 8.8 IL4R IL13 IL10

Sources for Lipoid Nephrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....